Global COVID-19 Nucleic Acid Testing Kits Market Size By Type (Fluorescent PCR, Thermostatic Amplification Chip), By Application (Hospital, Scientific Research), By Region, And Segment Forecasts, 2023...

The Global COVID-19 Nucleic Acid Testing Kits Market was valued at USD 9.4 billion in 2023 and is projected to reach USD 13.6 billion by 2031, growing at a CAGR of 4.8% during the forecast period from 2023 to 2031. The market is primarily driven by sustained global surveillance efforts, the need for early and accurate detection of SARS-CoV-2 variants, and public health initiatives across emerging and developed nations. With COVID-19 transitioning into an endemic phase in many regions, nucleic acid testing (NAT) remains the gold standard for diagnostics, offering high sensitivity and specificity. These kits are instrumental for clinical diagnostics, screening at airports and borders, and managing public health strategies during localized outbreaks.

Drivers:

1. Continued Need for Accurate Diagnostics:

Despite the shift from pandemic to endemic, global healthcare systems continue to depend on reliable COVID-19 detection tools to monitor new variants and manage outbreaks. Nucleic acid testing kits, particularly RT-PCR-based assays, remain the preferred method due to their precision.

2. Rise of Variant Surveillance Programs:

Governments and research bodies are investing in large-scale genomic and molecular testing programs. Nucleic acid testing plays a critical role in identifying mutations and emerging strains of concern, which is crucial for vaccine updates and public health decisions.

3. Growing Testing Infrastructure in Developing Regions:

As international aid and local investments boost healthcare capacity in Africa, Southeast Asia, and Latin America, adoption of nucleic acid testing kits has increased, enabling early detection and containment of viral spread in these regions.

Restraints:

1. Declining Mass Testing in Developed Nations:

As countries phase out mass testing programs and move toward targeted testing, especially for asymptomatic individuals, demand for nucleic acid testing kits in some high-income countries has slightly declined post-2022.

2. High Operational Cost and Technical Requirements:

These tests require advanced lab infrastructure, trained personnel, and longer turnaround times compared to rapid antigen kits, posing a challenge in resource-limited settings.

Opportunity:

1. Integration with Multiplex Diagnostic Platforms:

Manufacturers are expanding capabilities of nucleic acid kits to detect multiple respiratory pathogens (e.g., SARS-CoV-2, Influenza A/B, RSV) in a single test, creating opportunities for product differentiation and broader market adoption.

2. Expansion in At-home and Point-of-Care Testing Kits:

There is rising demand for portable, user-friendly NAT kits approved for home or decentralized clinical settings. Innovations in microfluidics and isothermal amplification are enabling more accessible solutions globally.

Market by System Type Insights:

The RT-PCR (Reverse Transcription Polymerase Chain Reaction) segment held the largest market share in 2023. Recognized for its superior accuracy, RT-PCR is widely used in hospitals, diagnostic labs, and border control points. However, the Loop-mediated Isothermal Amplification (LAMP) segment is expected to grow significantly due to its rapid detection capability and minimal equipment requirements, making it ideal for remote or resource-limited settings.

Market by End-use Insights:

Hospitals and Diagnostic Laboratories emerged as the largest end-users in 2023, collectively accounting for over 60% of the market share. These settings demand high-throughput, accurate testing for effective patient management and outbreak control. Meanwhile, the Point-of-Care (POC) segment is witnessing rapid growth, driven by the increasing need for rapid results and decentralized testing in airports, clinics, and home settings.

Market by Regional Insights:

North America dominated the market in 2023, driven by robust testing infrastructure, high public awareness, and continued government funding. However, Asia-Pacific is expected to be the fastest-growing region during the forecast period, supported by large-scale public health testing initiatives, technological adoption, and growing demand for decentralized diagnostic solutions in countries like India, China, and Indonesia.

Competitive Scenario:

Key players operating in the global COVID-19 nucleic acid testing kits market include Thermo Fisher Scientific Inc., Roche Diagnostics, Abbott Laboratories, BGI Group, Seegene Inc., Bio-Rad Laboratories Inc., QuidelOrtho Corporation, Danaher Corporation, PerkinElmer Inc., and GenScript Biotech. These companies are focusing on advancing test accuracy, expanding multiplex panels, and introducing portable NAT kits to strengthen their position.

Key Market Developments:

2023: Roche Diagnostics launched a multiplex NAT kit that simultaneously detects SARS-CoV-2, Influenza A/B, and RSV.

2024: BGI Group expanded its mobile NAT lab services in Southeast Asia for rapid outbreak response.

2025: Thermo Fisher introduced an ultra-fast RT-PCR testing system with results in under 20 minutes, targeting urgent care and emergency settings.

Scope of Work – Global COVID-19 Nucleic Acid Testing Kits Market

Report Metric Details

Market Size (2023) USD 9.4 billion

Projected Market Size (2031) USD 13.6 billion

CAGR (2023–2031) 4.8%

Key Segments by System Type RT-PCR, LAMP, CRISPR-based Tests

Key Segments by End-use Hospitals, Diagnostic Labs, Point-of-Care

Leading Region North America

Key Players Roche Diagnostics, Abbott, Thermo Fisher, BGI Group, Bio-Rad

FAQs:

1) What is the current market size of the Global COVID-19 Nucleic Acid Testing Kits Market?

The market was valued at USD 9.4 billion in 2023.

2) What is the major growth driver of the Global COVID-19 Nucleic Acid Testing Kits Market?

The major driver is the continued global need for accurate and sensitive testing to detect emerging COVID-19 variants.

3) Which is the largest region during the forecast period in the Global COVID-19 Nucleic Acid Testing Kits Market?

North America is the largest region, owing to strong healthcare infrastructure and continued public testing initiatives.

4) Which segment accounted for the largest market share in the Global COVID-19 Nucleic Acid Testing Kits Market?

The RT-PCR segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global COVID-19 Nucleic Acid Testing Kits Market?

Key players include Roche Diagnostics, Thermo Fisher Scientific, Abbott Laboratories, BGI Group, and Seegene Inc.

Would you like this formatted into a downloadable document as well?